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ScienceDirectBacteria do not live anchoretic; rather they are constantly in
touch with their eukaryotic hosts and with other bacteria
sharing their habitat. Therefore, bacteria have evolved
sophisticated proteinaceous weapons. To harm other bacteria,
they produce antibacterial effector proteins, which they either
release into the environment or export via direct intercellular
contact. Contact-dependent killing is mediated by two
specialized secretion systems, the type V and VI secretion
system, whereas contact-independent processes hijack other
transport mechanisms. Regardless of the transport system,
cells co-express immunity proteins to protect themselves from
suicide and fratricide. In general, effector protein activities and
secretion mechanisms differ between Gram-positive and
Gram-negative bacteria and evidence is emerging that different
effector/immunity systems act synergistically and thus extend
the bacterial armory.
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Introduction
Bacteria produce a multitude of effector proteins which
they either export into their environment or directly into
other cells. These effector molecules are targeted against
eukaryotic host cells where they promote pathogenicity as
virulence factors (reviewed in [1]). Additionally, effector
proteins are also used to compete with or even to gain
advantage over other species during bacterial warfare
within the microbiome. In the latter case, cells co-produce
Open access under CC BY-NC-ND license.www.sciencedirect.com immunity proteins to protect themselves from suicide or
fratricide. Export of effector proteins is accomplished by
secretion systems (SSs) that are classified according to the
transported effector molecules, their targets as well as the
producing cell type (Gram-negative or Gram-positive)
(reviewed in [2–4]). The general secretion (Sec) and the
two-arginine translocation (Tat) pathways and the type IV
secretion system (T4SS) are found in both bacterial cell
types. In contrast, the T1SS, T2SS, T3SS, T5SS, and the
recently discovered T6SS have only been identified in
the genome of Gram-negative bacteria, whereas the
T7SS has been exclusively found in Gram-positive
Mycobacteria. Depending on the secretion system, the
effector proteins are either exported into the environ-
ment (T1SS, T2SS, T7SS) or are directly transported into
the target cell upon physical contact (T3SS, T4SS, T5SS,
T6SS). Bacteria have evolved several different secretion
systems but only three (T5SS, T6SS, T7SS) have been
reported to be used in bacterial growth competition. The
other secretion systems have been reported to exclu-
sively target eukaryotic cells and transport virulence
factors (reviewed in [2,5]).
This article reviews the current knowledge of antibacter-
ial effector/immunity systems, classified into released or
injected effector proteins and discusses similarities and
differences between antibacterial effector/immunity sys-
tems and the well-known toxin/antitoxin systems.
Contact-independent antibacterial
systems — the bacteriocins
Bacteriocins are effector proteins that are released by
bacteria into their environment and are the best charac-
terized antibacterial effector proteins to date (reviewed in
[6,7]). They are widespread among all bacterial species
and are synthesized by ribosomes together with a cognate
immunity protein that protects bacteria from their own or
their sibling’s bacteriocins [6,7]. In this respect, bacter-
iocins are different to antibiotics such as vancomycin,
which are produced by non-ribosomal peptide synthe-
tases. Bacteriocins have a narrow spectrum of activity and
primarily act on closely related species. They are highly
diverse in terms of their activities, amino acid sequences
and three-dimensional structures [6,7]. Similarly, archaea
produce archaeocins to gain growth advantages over their
rivals (reviewed in [6]). Although archaeocins have been
predicted to be a general feature of haloarchaea [8], only
eight different halophilic strains (halocins) and Sulfolobus
islandicus (sulfolobicins) have been reported to express
such a system [6].Current Opinion in Microbiology 2014, 17:1–10
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bacteria
Gram-negative bacteriocins are named after the produ-
cing bacteria followed by the suffix -cin, with colicins from
Escherichia coli being the founding and most extensively
investigated members (reviewed in [7]). These bacter-
iocins are encoded from a single operon together with
their cognate immunity protein. Whereas most operons
also encode a lysis protein that induces autolysis for
effector protein release (Figure 1a), only a few bacter-
iocins are released by cell wall leakage. Notably, the lysis
proteins are highly conserved and functionally inter-
changeable between different strains [7]. Gram-negative
bacteriocins generally consist of three domains; a trans-
location (N-terminal), a receptor binding (central) and a
killing domain (C-terminal). The central domain hijacks
specific receptor proteins that are usually responsible for
nutrient uptake (Figure 1a). These receptors are highly
diverse among bacteria leading to a narrow killing
spectrum of bacteriocins [7]. Import of bacteriocins is
mediated by the recipient’s Ton or Tol system
(Figure 1a) [7,9,10]. These systems have been reported
to make use of a proton motive force for dissociation of the
tightly bound immunity proteins from the effector
protein [10] and also for translocation of the bacteriocins
into the target cell (reviewed in [9]). Except for colicin M,
which hydrolyzes peptidoglycan precursors [11] and pes-
ticin from Yersinia pestis, which possesses muramidase
activity [12], all other Gram-negative bacteriocins have
either pore forming or nuclease activity (Figure 1a) [7].
Bacteriocins produced by Gram-positive
bacteria
In contrast to their Gram-negative relatives, Gram-
positive bacteriocins have a broad killing spectrum, and
some of them even target Gram-negative bacteria
(reviewed in [6,13,14]). Since Gram-positive bacteriocins
simply diffuse through their target’s cell wall, they have a
very broad killing spectrum [14]. Furthermore, when
compared to Gram-negative bacteriocins, they are found
in large gene clusters and their production relies on
specific regulatory and transport factors [13]. Thus,
Gram-positive bacteria survive bacteriocin release,
whereas most Gram-negative bacteria undergo autolysis
for effector protein release [13,14]. Gram-positive bac-
teria, particularly lactic acid bacteria, produce a plethora
of different bacterocins which are either small peptides or
proteins with a molecular weight of more than 30 kDa and
are grouped into four major classes: The well-known
lantibiotics (class I), small heat-stable peptides (class
II), heat-labile proteins that kill bacteria by either lytic
or non-lytic mechanisms (class III) and cyclic peptides of
which the mechanism of function is still elusive [6].
However, all these bacteriocins do not belong to the
classical effector/immunity systems and are often referred
to as bacteriocin-like effectors, since they are either smallCurrent Opinion in Microbiology 2014, 17:1–10 peptides, or do not possess any enzymatic activity or lack
an immunity protein when they are classical enzymes.
The exception to the rule is the ribonuclease Barnase
from Bacillus amyloliquefaciens [15]. Although Barnase and
its cognate immunity protein Barstar [16] were identified
50 years ago, their putative antibacterial effector/immu-
nity function is exclusively predicted based on similarities
to bacteriocins and is still hypothetical. An antibacterial
activity was suggested since E. coli cells expressing Bar-
nase inhibit the growth of other bacteria and expression of
Barstar confers immunity [17]. However, no direct evi-
dence has been reported so far that B. amyloliquefaciens
harms other bacteria using Barnase and the mechanism by
which Barnase enters bacteria is also still elusive.
Contact-dependent antibacterial systems
Apart from simple secretion of effector proteins into the
environment, bacteria also kill others by establishing
intercellular contacts. Two different contact-dependent
systems have been described so far: the contact-depend-
ent growth inhibition (CDI) and the T6SS effector/
immunity systems.
‘Toxin on a stick’ — contact-dependent
growth inhibition
Contact dependent growth inhibition (CDI) by the E. coli
EC93 isolate is evoked by the cdiBAI operon [18]. CdiA is
the effector protein consisting of two domains, a large
conserved N-terminal domain (NtD) and a smaller C-
terminal antibacterial effector domain (CdiA-CT) respon-
sible for dissipating the proton motive force of the tar-
geted cell [19]. The CdiI protein provides immunity by
complex formation with CdiA effector molecules which
have been secreted by siblings. Secretion of CdiA relies
on CdiB, which has been predicted to be a channel-
forming protein (Figure 1b) [18,20]. The CdiA effector
is a large protein (about 300 kDa) and was predicted to
protrude from the surface by several nanometers. The N-
terminal domain of CdiA binds to the outer membrane
receptor BamA of the target cell [21] and thereby estab-
lishes a direct physical contact [18]. Subsequently, CdiA-
CT is most likely autoproteolytically cleaved from the N-
terminal domain and assimilated into the competitor cell
[18].
However, CDI systems are much more prevalent in the
genome of protebacteria than previously expected. A
bioinformatic search for putative effector variants
revealed an entire family of CDI operons with a con-
served N-terminal BamA binding domain [22]. The
toxic CdiA-CT domain, however, shows a significant
degree of polymorphism with tRNase, DNase or pore
forming activities [19,22]. Although these polymorphic
CdiA proteins are generally conserved in their N-terminal
domain, specificity for extracellular loop regions of the
BamA receptor of different bacterial species is achievedwww.sciencedirect.com
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Secretion mechanism and mode of action of the different antibacterial effector/immunity systems. (a) Release of Gram-negative bacteriocins (purple) is
a lethal event for the producer cell as it is accomplished by a lysis protein (red). Extracellular released bacteriocins are incorporated into the host cell by
receptors (dark blue) usually responsible for nutrient uptake. Translocated into the host periplasm (HP), bacteriocins are either integrated into the
host’s outer membrane (HOM) or further transported across the host’s inner membrane (HIM). Transport across the HIM is performed by the energy
dependent Ton or Tol system (light blue). Furthermore, the immunity proteins (spheres colored in purple) are only released in the host cell before Ton/
Tol import. Gram-negative bacteriocins have RNase or DNase activity and degrade tRNAs, mRNAs or DNAs of the host cells. (b) T5SSs are composed
of two components CdiA (magenta) and CdiB (green) that are exported into the periplasm of the producer cell via their Sec-system (yellow). CdiB is a
b-barrel forming protein that forms a pore in the outer membrane (OM) of the producer cell and transports CdiA across the OM. CdiA is presented on
the cell surface and binds to the BamA receptor (dark blue) of host cells upon direct cell–cell contact. BamA transports CdiA across the HOM into the
periplasm where it is either integrated into the membrane or further transported into the host cytoplasm (HC) by a yet unknown mechanism. CidA
proteins harbor nuclease activity and inhibit bacterial cell growth by degrading tRNA or DNA of the host cell. Furthermore, to prevent suicide and
fratricide, the donor cells co-express CdiI immunity proteins (magenta spheres). (c) The T6SS transports effector proteins directly into competing
bacterial cells. Hcp and VgrG are highly conserved among all T6SSs and homologous to the bacteriophage tip and tube components, respectively.
Assembly and disassembly of the T6SS needle is driven by ATP hydrolysis performed by ClpV. Three main classes of antibacterial T6SS effector
proteins have been identified, which are active on three distinct cellular compartments of the host cell: periplasm (red), lipid bilayer (orange) or the
cytoplasm (blue). On the basis of these workplaces the cognate immunity proteins (spheres colored according to the corresponding effector) are also
either localized in the periplasm, membrane or in the cytoplasm of the producer cell. Effector proteins that degrade the bacterial peptidoglycan
scaffold show either amidase or glycoside hydrolase activity. Effector proteins with phospholipase activity lead to cell lysis by modifying the
composition of the lipid bilayer. The mechanisms and targets of cytoplasmic active effector proteins are still elusive. C: cytoplasm, IM: inner
membrane, P: periplasm, OM: outer membrane, ECM: extracellular milieu, HOM: host outer membrane, HP: host periplasm, HIM: host inner
membrane, HC: host cytoplasm.
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4 Host–microbe interactions: bacteriaby sequence variations [23]. Thereby, CDI systems
achieve specificity for their target cells and establish a
narrow killing spectrum as observed for Gram-negative
bacteriocins [20,22]. Furthermore, CDI operons always
contain a small ORF located downstream of the CdiA
locus. These ORFs have been predicted to encode for the
cognate immunity proteins. For systems where the func-
tion has been experimentally verified, it became evident
that the immunity proteins are also polymorphic and do
not show any cross-reactivity with other CdiA effectors
[22,24].
Downstream of many of these polymorphic CDI loci,
potential genes of so called ‘orphan’ cdiA-CT/cdiI modules
are found. Whereas the cdiA-CT gene is translationally
silent, the cdiI ORF is expressed, but its function is still
elusive. Fusion of such an orphan cdiA-CT gene to the
NtD of the upstream and functional cdiA gene resulted in
an active protein secreted by CdiB. Turning on such
orphan cdiA-CT/cdiI genes by homologous recombination
could enable bacteria to rapidly diversify their CDI
systems and enable them to express a set of CdiI proteins
for broad range immunity [25].
Strikingly, CDI loci have also been identified in re-
arrangement hotspot (rhs) elements, which are genomic
regions that facilitate recombination in E. coli [25,26].
Rhs proteins have a conserved N-terminal region, which
differs from the BamA receptor binding domain of CdiA
proteins and a C-terminal, variable effector domain
[25,26]. Similar to CdiI, a cognate RhsI immunity
protein is encoded from the same operon but the chan-
nel-forming CdiB is missing [25]. Notably, CDI is not
restricted to Gram-negative bacteria, and homologous
proteins are also found in Gram-positive species like
members of the genera Bacillus, Listeria, Clostridium
and Streptococcus [27]. In fact, PF04740 proteins share
conserved N-terminal domains and their C-terminal
domains (CtDs) are homologous to the Gram-negative
CdiA-CTs. The CtDs of B. subtilis and B. cereus have been
experimentally shown to harbor RNase activity [27].
Furthermore, the ORFs downstream of the PF04740
locus encode small proteins which block growth inhi-
bition, indicative for a functional effector/immunity pair.
Similarly, the wall-associated proteins A (WapA) from
various B. subtilis strains have variable C-terminal effec-
tor domains and an associated immunity protein WapI. In
common, no ORF encoding for an orthologous channel-
forming CdiB protein has been identified for these Gram-
positive CDI-related effector/immunity systems and
effector presentation at the surface must be accom-
plished by a different mechanism. Since the N-terminal
domains of PF04740 proteins contain T7SS-specific
secretion signals, export is most likely performed by this
particular SS [27,28]. In contrast, WapA proteins carry an
N-terminal signal sequence responsible for cell wall
binding [27–29].Current Opinion in Microbiology 2014, 17:1–10 The number of putative polymorphic effector proteins
has been increased even more by a recent bioinformatic
study which identified a plethora of C-terminal toxic
domains with homologous large NtDs [30]. The toxic
activities of the C-terminal domains vary and range from
nuclease, deaminase, ADP-ribosyltransferase, peptidase
and phospholipase to pore-forming activity. All of these
putative polymorphic effector proteins are encoded from
an operon together with a small ORF that most likely
encodes the cognate immunity proteins [30]. However, it
remains to be shown if and how these polymorphic
putative toxins are secreted and what their role in bac-
terial warfare is.
‘Molecular syringes’ — effector proteins
injected by the type VI secretion system
Type VI secretion systems (T6SSs) are found in the
genome of approximately 25% of the different bacterial
species [31,32]. The T6SS injects a plethora of different
effector proteins into target cells by an upside-down
bacteriophage-like syringe (reviewed in [3,33]). Whereas
anti-eukaryotic T6SS effector proteins and their role in
pathogenesis have been extensively investigated
(reviewed in [34–36]), the functional mechanisms and
the regulation of antibacterial effector proteins are just
starting to be resolved.
The first antibacterial effector proteins secreted by a
T6SS were found in the genome of P. aeruginosa and
named Tse1-3 (type VI secretion exported 1–3) [37].
Tse1 and Tse3 act exclusively in the periplasm where
they hydrolyze peptidoglycan and thereby provoke lysis
of competing bacterial cells [38]. As with bacteriocins,
carriers of an active T6SS co-express the immunity
proteins Tsi1 and Tsi3 (type VI secretion immunity 1
and 3) from a common operon. Both immunity proteins
harbor an N-terminal signal sequence for translocation
into the periplasm to prevent fratricide [38]. In contrast,
the third effector/immunity pair, Tse2 and Tsi2, is cyto-
plasmic localized and kills bacteria by an unknown mech-
anism (Table 1) [37,39].
T6SS effector proteins with amidase activity
The discovery of the amidase activity of Tae1 (formerly
referred as Tse1) led to the assignment of a plethora of
previously hypothetical ORFs to an entire family of effec-
tor proteins that hydrolyse the muropeptide stems in the
peptidoglycan scaffold [40] (Figure 2). On the basis of
their cleavage specificity, these effectors were classified
into four groups (type VI amidase effector Tae1-4) (Table
1). Structural characterization of these amidase effector
proteins revealed a common N1pC/P60 peptidase core.
Distinct structural differences clustering around the active
site were observed, which probably reflect the different
substrate specificities [41,42,43–49]. Whereas the ami-
dase activity of these effector proteins is caused by a strictly
conserved cysteine-histidine dyad in their active sites andwww.sciencedirect.com
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Table 1
Enzymatic activity, targets and immunity proteins of the different antibacterial T6SS effector proteins
Effector Enzymatic activity Target Immunity Reference
Tae1 (Tse1) Amidase Peptidoglycan
(mDAP-D-Glu)
Tai1 (Tsi1) [37,38,40]
Tae2 Amidase Peptidoglycan
(mDAP-D-Ala)
Tai2 [40]
Tae3 Amidase Peptidoglycan
(mDAP-D-Ala)
Tai3 [40]
Tae4 Amidase Peptidoglycan
(mDAP-D-Glu)
Tai4 [40]
Tse2 Unknown Unknown Tsi2 [37,39]
Tge1 (Tse3) b-(1,4)-N-acetylmuramidase Peptidoglycan
(MurNAc-GlcNAc)
Tgi1 (Tsi3) [37,38,50]
Tge2 N-acetylglucosaminidase Peptidoglycan
(GlcNAc-MurNAc)
Tgi2 [50]
Tge3 b-(1,4)-N-acetylmuramidase Peptidoglycan
(MurNAc-GlcNAc)
Tgi3 [50]
Tle1 Phospholipase A2 Plasma membrane Tli1 [54
]
Tle2 Phospholipase A1 Plasma membrane Tli2 [53,54
]
Tle3 Phospholipase Plasma membrane Tli3 [54]
Tle4 Phopsholipase Plasma membrane Tli4 [54]
Tle5 Phospholipase D Plasma membrane Tli5 [54]
Vgr-3 Unknown Peptidoglycan TsaB [53,56]
Former names of the T6SS effector proteins are given in brackets.
GlcNAc: N-acetylglucosamine; MurNAc: N-acetylmuramic acid; D-Ala: D-alanine; D-Glu: g-D-glutamic acid; mDAP: meso-diaminopimelic acid.the proteins are structurally homologous, their cognate
immunity proteins are totally different and share no
homology [41,42,43,46,47,49] (Figure 3).
T6SS effector proteins with glycoside
hydrolase activity
Furthermore, the identification of the muramidase
activity of Tse3 from P. aeruginosa (renamed to
Tge1PA/Tgi1PA) enabled the identification of three
new classes of T6SS glycoside hydrolase effector (Tge)
proteins and their cognate immunity proteins (Tgi)
(Table 1) [50]. These effector proteins cleave the b-
1,4-glycosidic bond between MurNAc and GlcNAc in
the peptidoglycan scaffold. On the basis of their sequence
homology to other glycoside hydrolases, Tge1-3 were
suggested to differ in their cleavage mechanism: lytic
transglycosylase (Tge1), N-acetylglycosamidase (Tge2)
and phage-type lysozyme (Tge3) (Figure 2). Crystal
structures of Tge1 from P. aeruginosa [51,52] and Tge2
from Pseudomonas putida [50] in complex with their cog-
nate immunity proteins have revealed how different
effector proteins of this family acquire related glycoside
hydrolase activity and are inhibited by non-related immu-
nity proteins.
T6SS effector proteins with phospholipase
activity
Finally, antibacterial effector proteins that possess phos-
pholipase activity were identified in P. aeruginosa, Bur-
kholderia thailandensis and Vibrio cholerae [53,54]. Thesewww.sciencedirect.com enzymes modify the cell wall composition of competitors
and were named Tle (type VI lipase effector) and their
corresponding immunity proteins Tli (type VI lipase
immunity). ORFs encoding for Tle proteins were ident-
ified in many other Gram-negative bacteria. On the basis
of sequence homology and their phospholipase A1-like,
A2-like and D-like activities, these proteins were grouped
into 5 different families, Tle1-5 (Table 1) [53,54]. Nota-
bly, T6SS effector lipases harboring both antibacterial
and anti-eukaryotic killing activities were reported,
suggesting that they play an important role in bacterial
pathogenicity [53,55].
T6SS scaffold proteins with antibacterial
activity
T6SSs not only secrete effector proteins, but also some of
their structural components have killing potential (Table
1) [53,56]. Variations of the VgrG (valine-glycine repeat
G) protein which is functionally related to the bacterio-
phage spike proteins (reviewed in [3]), were reported to
be secreted and to harbor killing activity. For instance,
the ‘evolved’ VgrG-3VC from V. cholera contains a C-
terminal, lysozyme-like peptidoglycan binding domain
and hydrolyzes the cell wall of Gram-negative competi-
tors [53,56]. VgrG-3VC was suggested to be part of a
functional effector immunity pair, since the downstream
gene product encodes the cognate immunity protein
TsaB [53,56]. Since VgrG proteins form the tip of the
T6SS syringe, other functions apart from solely inducing
cell lysis are also conceivable. For instance, peptidoglycanCurrent Opinion in Microbiology 2014, 17:1–10
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Figure 2
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Peptidoglycan cleavage specificity of the different amidase and glycoside hydrolase effector protein families. Cleavage specificity of Tae1-4 on
pentapeptide (left panel) and tetrapeptide (right panel) stems of bacterial peptidoglycan is illustrated according to [38,40]. Effector proteins that
belong to the Tae2 and Tae3 family hydrolyze the cross-link between mDAP and D-Ala in tetrapeptides as well as in pentapeptides. In contrast, Tae1
and Tae4 effector proteins degrade the peptidoglycan by hydrolyzing the amide bond formed between g-D-Glu and mDAP. Whereas, Tae1 effector
proteins, including the founding member Tse1 from Pseudomonas aeruginosa, specifically cleave the donor stem of cross-linked tetrapeptides, Tae4
effector proteins exclusively degrade acceptor stems of cross-linked as well as non-crosslinked tetrapeptides. Furthermore, pentapeptides can also
be degraded by Tae4 family members but with a poor turnover rate. Additionally, bacteria express effector proteins with glycoside hydrolase activity
and degrade the peptidoglycan scaffold by cleaving the bond between the sugar moieties. Classification of these Tge proteins is according to [50].
Tge1 (including Tse3 from P. aeruginosa) and Tge3 effector proteins cleave the b-(1,4) glycosidic bond between MurNAc and GlucNAc by their b-(1,4)-
N-acetylmuramidase activity. In contrast, Tge2 effector proteins possess N-acetylglucosaminidase activity and hydrolyze the b-(1,4) glycosidic bond
between GlcNAc and MurNAc. Figure has been adapted from [47]. GlcNAc: N-acetylglucosamine; MurNAc: N-acetylmuramic acid; D-Ala: D-alanine; L-
Ala: L-alanine; D-Glu: g-D-glutamic acid; mDAP: meso-diaminopimelic acid.degradation by VgrG-3 could facilitate penetration
through the producer’s cell envelope during needle for-
mation [56]. ‘Evolved’ VgrG proteins could act as an
advance guard by increasing the cell wall permeability of
other bacteria and thereby facilitating injection or infu-
sion of other effector proteins. A stealthy penetration of
effector proteins into the competitor cell by VgrG
proteins is further supported by physical interaction be-
tween VgrG-3VC and the phospholipase effector Tle2VC
[53]. Finally, it remains to be shown whether cell wall
hydrolysis activity of ‘evolved’ VgrG proteins is also used
to attack Gram-positive bacteria.
T66S effector proteins are commonly used
antibacterial weapons
Evidence is emerging that the T6SS effector/immunity
proteins characterized so far are just the tip of the iceberg
and that the bacterial armory is more extensive and
complex than previously thought. For instance, different
Acinetobacter baumannii strains contain conserved T6SS
loci [57,58], however, not all of them exhibit killing
activity towards other bacteria under the conditions
tested [58]. This suggests that effector protein secretionCurrent Opinion in Microbiology 2014, 17:1–10 is strictly regulated and not activated by common mech-
anisms, even not in closely related species. Moreover,
effector proteins might even not be secreted under
laboratory conditions or are only activated under certain
conditions. This hypothesis is further supported by the
failure to detect any T6SS activity in re-cultured pan-
demic V. cholera strains under laboratory conditions [59].
Additionally, antibacterial T6SS activity was identified in
various bacteria but no effector proteins could be assigned
yet [57,60]. In other studies, putative effector proteins
could be identified, but their killing activity and cellular
targets are still elusive [37,39,61].
Effector/immunity systems and other
toxins — an interdisciplinary assassination
team?
Effector/immunity and type II toxin/antitoxin (TA) sys-
tems are often spuriously mixed, as both induce cell
death in bacteria and their genomic organization in
bicistronic operons is related. However, there is a funda-
mental, functional difference between the two systems.
Effector proteins are released and serve to attack com-
petitors and the stable immunity proteins providewww.sciencedirect.com
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Structural overview of the effector/immunity system Tae1/Tai1 from
Pseudomonas aeruginosa, Tae3/Tai3 from Ralstonia pickettii and Tae4/
Tai4 from Salmonella typhimurium. (a) Schematic representation of the
www.sciencedirect.com long-term protection against siblings [39]. In contrast,
toxin proteins rest inside the cell and the unstable anti-
toxin provides only temporary protection and thus toxin/
antitoxin systems induce bacterial suicide upon acti-
vation (reviewed in [62]).
But evidence is emerging that both systems have com-
mon origins and/or overlapping functions and a strict
separation is not always possible. For instance, both
systems are often found within mobile genetic elements,
pathogenicity islands and transposon-like regions
(reviewed in [7,22,63,64]). It remains to be shown
whether TA toxins are translocated in addition to effector
proteins by SSs and directly used as weapons against
competitors. Such a hijack of the T6SS by non-related
T6SS toxins has been shown, for instance for the Rhs
proteins of Serratia marcescens [61] and Dickeya dadantii
[25,26]. As Rhs loci do not encode for any CdiB hom-
ologue nor do Rhs proteins harbor any leader sequence for
CdiB-dependent transport they need to hijack other SSs
[25]. Transport via the T6SS is rather likely, since RhsTae1/Tai1 effector/immunity complex from P. aerugionsa. Tae1 (red) and
Tai1 (blue) form a heterodimer. The effector protein’s toxicity is inhibited
by a conserved serine residue (Ser109) located in a loop region of Tai1
that prevents effector protein activation and substrate binding. (b)
Crystal structure of the effector protein Tae1 (PDB code 4FGE) with the
conserved NlpC/P60 catalytic core in gray. Secondary structure
elements, which are specific for Tae1, are colored in red. The catalytic
important Cys30 and His91 residues are depicted as stick model and
highlighted with an orange rectangle. (c) Crystal structure of the Tae1
and Tai1 heterodimer (PDB code 4FGI) colored in red and blue,
respectively. The inhibiting serine residue Ser109 as well as the catalytic
important residues Cys30 and His91 are depicted as sticks and
highlighted with an orange rectangle. (d) Schematic representation of
the Tae3/Tai3 effector/immunity complex from R. pickettii. Tae3 (green)
and Tai3 (yellow) form a heterohexamer. The effector protein’s toxicity is
inhibited by blocking substrate binding. (e) Crystal structure of the
effector protein Tae3 (PDB code 4HZ9) with the conserved NlpC/P60
catalytic core in gray. Secondary structure elements, which are specific
for Tae3, are colored in green. The catalytic important Cys23 and His81
residues are depicted as stick model and highlighted with an orange
rectangle. (f) Crystal structure of the Tae3 and Tai3 heterohexamer (PDB
code 4FGI) formed by two Tae3 (green) and four Tai3 (yellow and orange)
molecules. Similar to (e) the catalytic important Cys23 and His81
residues are depicted as sticks and the active site is highlighted with an
orange rectangle. (g) Schematic representation of the Tae4/Tai4
effector/immunity complex from S. typhimurium. Tae4 (cyan) and Tai4
(orange) form a heterotetramer. The effector protein’s toxicity is inhibited
by a conserved serine residue (Ser98) located in a loop region of Tai4
that prevents effector protein activation and substrate binding. (h)
Crystal structure of the effector protein Tae4 with the conserved NlpC/
P60 catalytic core in gray (PDB code 4J32). Secondary structure
elements, which are specific for Tae4, are colored in cyan. Cys44 and
His126 that form the catalytically active dyad are depicted as stick
model and highlighted with an orange rectangle. (i) Crystal structure of
the Tae4/Tai4 heterotetramer (PDB code 4J32). Two symmetry related
Tai4 molecules (orange) form a head-to-tail-dimer and inhibit two
opposing Tae4 effector proteins (cyan). As with Tai1, Ser98 in Tai4 is
located in a loop and is important for effector protein inhibition by
blocking the active site of Tae4 and by preventing Cys44 activation.
Residues in Tae4 as well as in Tai4 are depicted as sticks. The active site
and the inhibiting serine residue are highlighted with an orange
rectangle.
Current Opinion in Microbiology 2014, 17:1–10
8 Host–microbe interactions: bacterialoci are often found next to vgrG genes [25] and Rhs-
mediated bacterial growth inhibition relies on VgrG
proteins [26]. However, this transport might not be
accomplished through the injection needle, since the
diameter of the Hcp tube (40 A˚) [65] seems to be too
narrow for Rhs proteins. Most likely the conserved PAAR
(proline-alanine-alanine-arginine) repeat domain of Rhs
proteins localizes to the VgrG tip before assembly of the
tube [66]. Notably, many uncharacterized PAAR-repeat
proteins carry polymorphic C-terminal extensions with
enzymatic functions like nuclease, peptidase or lipase
activities and might fulfill similar functions [26,66].
Conclusion
Effector proteins involved in bacterial competition are a
highly polymorphic group of bacterial toxins that appar-
ently form an interdisciplinary and synergistic team to kill
competitors during warfare. It seems that just the tip of
the iceberg of this arsenal has been discovered and many
questions need to be answered before we fully under-
stand bacterial competition and communication and its
involvement in pathogenicity.
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